The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 17, 2022

Filed:

Jan. 31, 2020
Applicant:

Unm Rainforest Innovations, Albuquerque, NM (US);

Inventors:

Graham Timmins, Albuquerque, NM (US);

Vojo P. Deretic, Placitas, NM (US);

Assignee:

UNM Rainforest Innovations, Albuquerque, NM (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/137 (2006.01); A61P 11/00 (2006.01); A61P 31/06 (2006.01); A61K 31/136 (2006.01); A61K 51/04 (2006.01); A61K 35/00 (2006.01); C07C 213/08 (2006.01); A61K 31/395 (2006.01); A61K 9/00 (2006.01); C07C 215/42 (2006.01); C07B 59/00 (2006.01); A61P 31/04 (2006.01); C07C 215/68 (2006.01); A61K 45/06 (2006.01); A61K 45/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/137 (2013.01); A61K 9/0075 (2013.01); A61K 31/136 (2013.01); A61K 31/395 (2013.01); A61K 35/00 (2013.01); A61K 45/06 (2013.01); A61K 51/0402 (2013.01); A61P 11/00 (2018.01); A61P 31/04 (2018.01); A61P 31/06 (2018.01); C07B 59/001 (2013.01); C07C 213/08 (2013.01); C07C 215/42 (2013.01); C07C 215/68 (2013.01); A61K 45/00 (2013.01);
Abstract

The present invention is directed toC and/orH isotope enhanced ambroxol ('isotope enhanced ambroxol') and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drug resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent are useful against an autophagy mediated disease state and/or condition, for example, ainfection, Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer. Methods of treating autophagy disease states and/or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention. Methods of synthesizing compounds according to the present invention are disclosed herein.


Find Patent Forward Citations

Loading…